Joining the discussion are Victoria Nachar, an outpatient hematology pharmacist from the University of Michigan with expertise in lymphoma and myeloma, and James Davis, a malignant hematology pharmacist and assistant professor at MUSC, known for his deep knowledge in multiple myeloma. They explore the management of cytokine release syndrome (CRS) in patients receiving bispecific antibodies, comparing it to CAR-T therapies. They discuss current treatment strategies, the role of prophylactic tocilizumab, and the importance of tailored approaches in patient care.
